Akebia Positive Euro Opinion for XOANACYL for Chronic Kidney Disease Licensed to Averoa

Akebia Therapeutics (AKBA) announced that the European Medicines Agency's CHMP has adopted a positive opinion recommending approval for XOANACYL® (Ferric Citrate as Coordination Complex). The drug is intended for treating elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).

The treatment rights in the European Economic Area and certain countries in Europe and the Middle East are licensed to Averoa, a renal-focused biopharmaceutical company. The European Commission is expected to make a final decision on XOANACYL's approval in approximately two months.

https://www.stocktitan.net/news/AKBA/akebia-therapeutics-announces-positive-opinion-of-european-medicines-t2mbmahppcae.html